Description
Per tablet: 50 mg Sildenafil + 20 mg Tadalafil + 1 mg PT-141
Count: 50 tablets
What is ENVY?
ENVY is a combined research formulation that pairs two peripheral PDE-5 pathway agents (sildenafil + tadalafil) with PT-141, a centrally acting melanocortin receptor agonist peptide. In controlled research settings, this combo is explored for how vascular perfusion signaling and CNS arousal signaling may interact in sexual-health pathway models.
Research Focus Areas
Studies typically center on vascular/NO signaling, pelvic circulation pathways, central arousal/drive signaling, and male/female sexual-function pathway models—often looking at combined “peripheral + central” mechanisms.
Potential Research Benefits (models)
-
Vascular / NO signaling: blood-flow and vasodilation pathway research (PDE-5 related)
-
Performance endurance pathways: longer-duration perfusion signaling models (tadalafil half-life discussions in research)
-
Central arousal signaling: libido/drive pathway activation independent of blood flow (PT-141)
-
Male + female sexual-health models: psychogenic/peripheral synergy research frameworks
-
Vascular + neuro synergy: combined pathway studies (circulation + CNS signaling)
Cybergen Peptides: Research Use Disclaimer
All products offered by Cybergen Peptides are intended solely for laboratory, educational, and scientific research purposes. Supplied for in-vitro research only (“in glass”)—not for human or animal consumption, medical use, or diagnostic applications.
Cybergen Peptides compounds are not drugs, medicines, or dietary supplements and have not been evaluated or approved by the FDA or any other regulatory agency. Any form of bodily introduction or therapeutic application is strictly prohibited.
